the invention relates to the field of biology and medicine, and mainly relates to new antibiotics containing \u043c\u0438\u043c\u0435\u0442\u0438\u0447\u0435\u0441\u043a\u043e\u0435 antibody, the ways of receiving and the application of.a new antibiotic containing \u043c\u0438\u043c\u0435\u0442\u0438\u0447\u0435\u0441\u043a\u043e\u0435 antibody and \u043a\u043e\u043b\u0438\u0446\u0438\u043d or containing \u043c\u0438\u043c\u0435\u0442\u0438\u0447\u0435\u0441\u043a\u043e\u0435 antibody and \u043a\u0430\u043d\u0430\u043b\u043e\u043e\u0431\u0440\u0430\u0437\u0443\u044e\u0449\u0438\u0439 \u0434\u043e\u043c\u0435\u043d\u0442 \u043a\u043e\u043b\u0438\u0446\u0438\u043d\u0430,with the \u043c\u0438\u043c\u0435\u0442\u0438\u0447\u0435\u0441\u043a\u043e\u0435 antibody \u043a\u043e\u0432\u0430\u043b\u0435\u043d\u0442\u043d\u043e \u043f\u0440\u0438\u0441\u043e\u0435\u0434\u0435\u043d\u0435\u043d\u043e to \u043a\u0430\u0440\u0431\u043e\u043a\u0441\u0438\u043b\u044c\u043d\u043e\u043c\u0443 end \u043f\u043e\u043b\u0438\u043f\u0435\u043f\u0442\u0438\u0434\u0430 \u043a\u043e\u043b\u0438\u0446\u0438\u043d\u0430 or \u043a\u0430\u043d\u0430\u043b\u043e\u043e\u0431\u0440\u0430\u0437\u0443\u044e\u0449\u0435\u0433\u043e domain \u043a\u043e\u043b\u0438\u0446\u0438\u043d\u0430 and \u043a\u043e\u043b\u0438\u0446\u0438\u043d choose t of the groupwhich consists of \u043a\u043e\u043b\u0438\u0446\u0438\u043d\u0430 e1, ia, Ib, a, b, n, with the merger of two \u043c\u0438\u043c\u0435\u0442\u0438\u0447\u0435\u0441\u043a\u043e\u0435 antibody are \u0433\u0438\u043f\u0435\u0440\u0432\u0430\u0440\u0438\u0430\u0431\u0435\u043b\u044c\u043d\u044b\u0445 sites (CDRs)VHCDR1 and VLCDR through \u043a\u043e\u0433\u043d\u0430\u043d\u0442\u043d\u044b\u0439 \u043a\u0430\u0440\u043a\u0430\u0441\u043d\u044b\u0439 station (VHFR2) immunoglobulin and immunoglobulin specifically recognizes bacterial \u043f\u043e\u0440\u0438\u043d\u044b.thanks to this unique mechanism of action, resistance to drugs, the resulting mutation
